Jefferies Financial Group Inc. Lowers Position in Dynavax Technologies Corporation (NASDAQ:DVAX)

Jefferies Financial Group Inc. cut its stake in Dynavax Technologies Corporation (NASDAQ:DVAX - Free Report) by 75.7% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 46,800 shares of the biopharmaceutical company's stock after selling 145,974 shares during the period. Jefferies Financial Group Inc.'s holdings in Dynavax Technologies were worth $607,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Cambridge Investment Research Advisors Inc. bought a new stake in Dynavax Technologies during the first quarter worth about $312,000. GAMMA Investing LLC boosted its position in shares of Dynavax Technologies by 88.4% in the 1st quarter. GAMMA Investing LLC now owns 7,729 shares of the biopharmaceutical company's stock worth $100,000 after purchasing an additional 3,627 shares in the last quarter. First Trust Advisors LP bought a new stake in shares of Dynavax Technologies in the 4th quarter worth approximately $847,000. Schonfeld Strategic Advisors LLC grew its stake in shares of Dynavax Technologies by 97.6% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 310,430 shares of the biopharmaceutical company's stock worth $3,964,000 after buying an additional 153,302 shares during the last quarter. Finally, Deep Track Capital LP increased its position in Dynavax Technologies by 42.0% during the 4th quarter. Deep Track Capital LP now owns 17,791,486 shares of the biopharmaceutical company's stock valued at $227,197,000 after buying an additional 5,265,000 shares in the last quarter. 96.96% of the stock is owned by institutional investors.

Dynavax Technologies Stock Performance

Shares of Dynavax Technologies stock traded down $0.73 during trading on Friday, hitting $10.33. 4,776,516 shares of the company's stock traded hands, compared to its average volume of 1,250,229. Dynavax Technologies Corporation has a 1 year low of $9.22 and a 1 year high of $14.63. The business has a 50-day simple moving average of $10.50 and a 200-day simple moving average of $11.55. The stock has a market capitalization of $1.24 billion, a P/E ratio of -22.46 and a beta of 1.09. The company has a debt-to-equity ratio of 0.49, a current ratio of 11.93 and a quick ratio of 10.84.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $0.14 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.12 by $0.02. Dynavax Technologies had a negative net margin of 16.67% and a positive return on equity of 4.87%. The firm had revenue of $95.44 million for the quarter, compared to the consensus estimate of $87.55 million. As a group, analysts forecast that Dynavax Technologies Corporation will post 0.32 EPS for the current year.

Analyst Ratings Changes

Several brokerages have recently weighed in on DVAX. The Goldman Sachs Group reduced their price target on Dynavax Technologies from $12.00 to $10.00 and set a "sell" rating for the company in a report on Thursday, April 17th. Wall Street Zen upgraded shares of Dynavax Technologies from a "hold" rating to a "buy" rating in a research note on Saturday. Finally, JMP Securities upped their target price on shares of Dynavax Technologies from $31.00 to $32.00 and gave the stock a "market outperform" rating in a research note on Friday. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company's stock. According to MarketBeat, Dynavax Technologies has an average rating of "Moderate Buy" and a consensus target price of $24.33.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.